Abstract 4462
Background
Lung cancer is the leading cause of cancer mortality worldwide with more than 2 million new cases and 1.8 million deaths in 2018. The TTR could be of use to objectively understand the clinical reality of lung cancer in Spain.
Methods
Observational cohort multicenter study performed in Spain. Enrollment took place between Aug’16 and Dec’18. Evaluation included a review of demographic data.
Results
6600 patients in 56 Spanish hospitals were included. Median age at diagnosis was 64 in advanced disease and 65 in early-stage. The majority of patients presented with advanced, stage III (n = 1874, 28.4%) or IV (n = 3446, 52.2%) at diagnosis, independently of gender (63.1% in males; 70.6% in females). There was a higher number of patients with no comorbidities at diagnosis in advanced disease than in early-stage (63.4% vs. 36.6%, p < 0.001) Significant differences (p < 0.001, unless indicated) observed between the two groups in the prevalence of cardiopathy, dyslipidemia (p = 0.043), COPD, hypercholesterolemia (p = 0.026), hypertension, nephropathy (p = 0.012), obesity (p = 0.007) and vasculopathy. Prevalence of symptoms (cough, pain, dyspnea, hemoptysis, weight loss, anorexia, and asthenia) was higher (p < 0.001) in advanced disease. No association found between professional occupation and stage at diagnosis, but according to exposure to carcinogenic compounds. A higher % of patients with advanced disease was observed over exposed to arsenic compounds (87.5% vs. 65.1%, p = 0.02) and acrylonitrile (75.0% vs. 65.1%, p = 0.02). Early-stage disease more prevalent among patients exposed to asbestos (47.5% vs. 34.9%, p = 0.02), radon/silica (47.4% vs. 34.9%, p = 0.02) and paintings (38.1% vs. 34.9%, p = 0.02) and diesel smoke (38.2% vs. 34.9%, p = 0.02) More patients with personal history of cancer had early-stage vs advanced disease (47.6% vs. 34.9%, p < 0.001); no differences found in stage according to family history of cancer.
Conclusions
The RTT provides information on comorbidities, risk associations, personal and family history of cancer necessary for the knowledge of lung cancer in real life, which could even be useful when planning the analysis of national health policies.
Clinical trial identification
NCT02941458.
Editorial acknowledgement
Legal entity responsible for the study
Spanish Lung Cancer Group.
Funding
Novartis, MSD, Lilly.
Disclosure
M. Provencio: Advisory / Consultancy: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
2831 - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia
Presenter: Salah Khallaf
Session: Poster Display session 1
Resources:
Abstract
6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)
Presenter: Su-peng Yeh
Session: Poster Display session 1
Resources:
Abstract
2914 - Efficacy endpoints studied in clinical trials for early-onset leukaemia
Presenter: Dylan Said
Session: Poster Display session 1
Resources:
Abstract
4691 - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia
Presenter: Tomohiro Yamakawa
Session: Poster Display session 1
Resources:
Abstract
4395 - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Presenter: Suzanne Trudel
Session: Poster Display session 1
Resources:
Abstract
2808 - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Nathan Fowler
Session: Poster Display session 1
Resources:
Abstract
4403 - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Jonathon Cohen
Session: Poster Display session 1
Resources:
Abstract
3357 - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
2475 - Qualitative study of patients’ experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services
Presenter: Ana Martins
Session: Poster Display session 1
Resources:
Abstract
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract